Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta‐analysis of anti‐CTLA‐4 and anti‐PD‐1 agents trials-Reference-Cited by-同舟云学术

Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta‐analysis of anti‐CTLA‐4 and anti‐PD‐1 agents trials

Published:2016-05-11 Issue:7 Volume:5 Page:1481-1491
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Yun Seongseok¹²^ORCID,Vincelette Nicole D.³,Green Myke R.²,Wahner Hendrickson Andrea E.⁴,Abraham Ivo⁵⁶

Affiliation:

1. Department of Medicine University of Arizona Tucson Arizona 85721

2. Hematology and Oncology University of Arizona Tucson Arizona 85721

3. Molecular Pharmacology and Experimental Therapeutics Mayo Clinic Rochester Minnesota 55905

4. Medical Oncology Mayo Clinic Rochester Minnesota 55905

5. Center for Health Outcomes and PharmacoEconomic Research University of Arizona Tucson Arizona 85721

6. Arizona Cancer Center University of Arizona Tucson Arizona 85721

Funder

Mayo Foundation for Medical Education and Research

University of Arizona

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.732

Reference67 articles.

1. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

2. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

3. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

4. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

5. Enhancement of Antitumor Immunity by CTLA-4 Blockade

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unsupervised Analysis Reveals the Involvement of Key Immune Response Genes and the Matrisome in Resistance to BRAF and MEK Inhibitors in Melanoma;Cancers;2024-06-24

2. Changes in Global Quality of Life after treatment with immune checkpoint inhibitors in patients with advanced stage lung cancer in the Netherlands – a 2015-2021 cohort study;2024-04-30

3. Stimuli-Responsive Polymeric Nanomedicine for Enhanced Cancer Immunotherapy;Chemistry of Materials;2024-01-29

4. Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach;Biomedicines;2024-01-18

5. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies;Signal Transduction and Targeted Therapy;2023-12-18